Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 22,009 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Cancer Risk Factors, Cancer Prevention
Interventions: CARES4You Curriculum; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 10 Years and older
Enrollment: 1,812 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Brooklyn, New York • New York, New York • Queens, New York + 1 more

Conditions: Anaplastic Ependymoma, Ependymoma
Interventions: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 22 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Type 2 Diabetes
Interventions: THC, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Insulin Resistance, Polycystic Ovary Syndrome, Hyperinsulinism, Obesity, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Ali Chappell; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gram-negative Bacterial Infection
Interventions: Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 39 Weeks
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Healthy
Interventions: Experience sampling; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Interventions: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine, Granulocyte Colony-Stimulating Factor (G-CSF); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 26
States / cities: Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more

Conditions: Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions: Ubamatamab, Marlotamig, Sarilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more

Conditions: Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
Interventions: Ultrafiltration; Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteer
Interventions: MT-201; Drug
Lead sponsor: Mirador Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Graft vs. Host Disease
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 120 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 6,950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 120
States / cities: Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more

Conditions: Stroke
Interventions: Motor relearning training, Passive stretching, Gamed-based active movement training, Passive movement, Active movement training, Ankle torque and motion measurement; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 30 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Houston, Texas

Conditions: Endotracheal Extubation, Airway Anesthesia, Paediatric
Interventions: Direct removal of endotracheal tube, Laryngeal mask airway inserted following deep extubation; Procedure
Lead sponsor: Telethon Kids Institute; Other
Eligibility: 0 Years to 16 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Philadelphia, Pennsylvania

Conditions: Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Disease
Interventions: Edwards TRIFORMIS RESILIA heart valve; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Carmel, Indiana

Conditions: Advanced Solid Tumors With MAPK Pathway Mutations
Interventions: D3S-002, D3S-001; Drug
Lead sponsor: D3 Bio (Wuxi) Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Detroit, Michigan • New York, New York • Nashville, Tennessee + 1 more

Conditions: NSCLC
Interventions: Docetaxel, Paclitaxel, Gemcitabine, Pemetrexed, Vinorelbine; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: Non-hyperemic pressure ratio assessment pre and post PCI; Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anterior Cruciate Ligament Injuries
Interventions: Anakinra injection, sterile saline injection; Drug · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions: Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo; Dietary Supplement
Lead sponsor: Quantec Ltd; Industry
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Solid Tumor, Adult, Healthy Donors, COVID-19 Donors
Interventions: Not listed
Lead sponsor: BioCytics, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Huntersville, North Carolina

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 30
States / cities: Palo Alto, California • San Francisco, California • Miami, Florida + 23 more

Conditions: Congenital Heart Disease in Children
Interventions: Remote Cardiac Rehabilitation, Active Control; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 19 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions: Endoscopic ultrasound shear wave elastography; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Using Middle School Science Teachers to Address Cancer Health Disparities

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

THC Effects on Glucose in Type 2 Diabetes

Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Real-time fMRI for Insular Cortex Brain State-triggered Experience Sampling

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Dry Weight Reduction Intervention Via Extra Ultrafiltration

A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Facilitating Neuroplastic Changes of Acute Stroke Survivors

BELUGA: Better to Exchange ETT for LMA Before Extubation in Children Under General Anaesthesia

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI

Biologic Therapy to Prevent Osteoarthritis After ACL Injury

Immune Defense Protein Impact On Respiratory Immune Outcomes

A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Remote Cardiac Rehab for Adolescents With Congenital Heart Disease

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease